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For nearly 100 years, developmental biologists have
utilized fate mapping to understand the contributions of
progenitor populations to organogenesis. More recently,
Cre-Lox technology has allowed genetic fate mapping in
adult mice, clarifying cell hierarchies in adult kidney disease
models. In ischemia–reperfusion injury, genetic labeling of
epithelial cells has demonstrated that intrinsic epithelial cells
are responsible for nephron repair and not an interstitial
or other non-epithelial cell type. In fibrotic kidney injury, fate
mapping techniques have strongly challenged the theory
that epithelial cells traverse the basement membrane to
become myofibroblasts in a process of epithelial-to-
mesenchymal transition and also indicate that interstitial
pericytes/perivascular fibroblasts are the authentic
myofibroblast progenitor pool. This mini review will
summarize the fate mapping approach in mice, convey
recent developments in kidney disease models, and outline
future opportunities to apply this technology to better
understand the cellular mechanisms of adult kidney
homeostasis and disease.
Kidney International (2011) 79, 494–501; doi:10.1038/ki.2010.338;
published online 22 September 2010
KEYWORDS: acute renal failure; renal fibrosis; renal stem cell
INTRODUCTION: FATE MAPPING IN EMBRYOGENESIS
A fate map is the representation of a cell’s developmental
history back to an earlier stage and shows how a cell
moves and what it will become in development. The earliest
fate maps were published over a century ago based on direct
observation of invertebrate marine creatures such as the
ascidian or sea squirt.1 Modern fate mapping was introduced
by Walter Vogt in 1929 when he marked the surface of groups
of cells on the embryo with a dye, which allowed him to track
the movement of these cells during amphibian gastrulation.2
Subsequently, technical advances allowed the construction of
a higher resolution fate map through direct injection of vital
dyes, radioactive tracers or enzymatic markers like horse-
radish peroxidase into cells. These advances allowed cells to
be tracked for longer periods of time and to visualize their
movement within the embryo rather than on the surface.
Fundamental limitations of early fate mapping techniques
included the tendency of the marker to diffuse and dilution
of the marker with each round of cell division, limiting
resolution. The use of chimeras between species—chick-
quail, for example, in the case of neural crest migration,3
provided a powerful solution because nucleolar staining
patterns are distinct between these species, however, the
approach required surgery and chimeras rarely survived
after birth. Recently, the combination of transgenic and
gene targeting approaches with site-specific recombinases
has revolutionized fate mapping approaches in mouse
by providing sophisticated new methods for genetically
marking and tracing cell fate (genetic fate mapping).4,5
Because these technologies allow unambiguous definition of
the relationship between embryonic and adult structures,
genetic fate mapping has been one of the most important
tools in stem cell and regenerative biology and it now has
an increasingly prominent role in kidney research.
GENETIC FATE MAPPING TECHNIQUES
Genetic fate mapping involves a site-specific recombinase—
an enzyme that recognizes specific nucleotide sequences to
mediate DNA excision—to activate expression of a reporter
molecule such as b-galactosidase or green fluorescent protein
(GFP). In the absence of recombinase activity, a DNA cassette
upstream of the reporter prevents its expression. When this
‘STOP’ cassette is flanked by nucleotide sequences recognized
by the recombinase, expression of the recombinase results in
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excision of the STOP cassette, activating constitutive
expression of the reporter (Figure 1a). The reporter transgene
is integrated into the genome, therefore, expression is
heritable; all daughter cells inherit the recombined version
of the reporter such that both the ancestor and all descendent
cells continue to express the reporter (Figure 1b).
The site-specific recombinases typically utilized for genetic
fate mapping are either Cre recombinase (encoded by the
bacteriophage P1 and recognizes a 34 bp LoxP sequence) or
Flp recombinase (encoded by Saccharomyces cerevisiae and
recognizes a 34 bp flippase recognition target or FRT sequence,
see Table 1). Recombinase expression is driven by a cell-specific
promoter utilizing either transgenic or knock-in approaches
(for review, see Joyner and Zervas5). For temporal control of
recombination, a modified version of the estrogen receptor
ligand-binding domain has been fused to both Cre and Flp
(CreER, FlpER). In the absence of the tamoxifen ligand, the
recombinase is sequestered in cytoplasm, but administration
of tamoxifen allows translocation to nucleus where recombi-
nation can occur (Figure 1b).6
Reporter mouse Site-specific recombinase
Tissue-specific reporter expression
Tissue-specific
promoter
Cre pALacZR26 STOP TSP
LacZR26
loxP loxP
loxP
CreERHSP90
CreER
Tam
Heritable reporter expression
Figure 1 | Site-specific recombinases for genetic lineage analysis. (a) To accomplish genetic lineage analysis, a reporter mouse is crossed
to a site-specific recombinase-expressing mouse, or ‘Cre-driver’. The reporter allele consists of a ubiquitously expressed promoter, such as
R26, driving the expression of a floxed STOP cassette (often a triple polyadenylation sequence flanked by LoxP recognition sequences)
upstream of a reporter such as LacZ. In the second mouse, a recombinase such as Cre is expressed using a tissue-specific promoter (TSP).
In bigenic offspring, cells that express Cre recombinase express LacZ heritably because Cre mediates recombination of the LoxP sites,
excising the STOP cassette and allowing reporter expression. (b) To achieve temporal control of genetic fate mapping, one approach is to
utilize a Cre recombinase allele to which the ligand-binding domain of the estrogen receptor (ER) has been fused in frame (CreER). The ER
domain excludes the recombinase from the nucleus through binding to HSP90 in the cell cytoplasm. When an ER ligand is added such
as tamoxifen (Tam), the CreER fusion translocates to the nucleus where excision of the floxed STOP occurs, allowing fate marker expression.
As the reporter is present in genomic DNA, daughter cells will heritably express the fate marker after cell division.
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A variety of reporter alleles are now available (Table 2). All
contain a ubiquitous promoter such as R26 or cytomegalo-
virus early enhancer and chicken beta-actin promoter (CAG),
followed by a LoxP or FRT-flanked STOP sequence (typically
sequential polyadenylation sequences), followed by a reporter
gene, such as b-galactosidase, GFP, or red fluorescent protein
(RFP). Because the R26 promoter strength is relatively weak
in adult kidney, reporters that contain additional strong
promoters—such as the CAG promoter downstream of the
R26 locus—may be advisable to ensure strong signal detection.
THE ORIGIN OF REPARATIVE EPITHELIAL CELLS IN
ACUTE KIDNEY INJURY
We have applied genetic fate mapping to clarify the origin of
epithelial cells after acute kidney injury in mouse. The kidney
has a great capacity to repair after acute injury, and
historically, the robust epithelial proliferation seen 24–48
hours after ischemic injury has been held to reflect
dedifferentiation and reentry into the cell cycle of differ-
entiated cells that survived the insult.7,8 However, a number
of reports have challenged this notion, suggesting that: (a)
bone marrow stem cells migrate to kidney and differentiate
into epithelium or (b) an interstitial, non-epithelial stem
cell population might exist in adult kidney that could be
recruited after injury to supply epithelial progenitors and
contribute directly to nephron repair. These putative kidney
stem/progenitor populations have been identified by BrdU
label retention, or putative stem cell markers (Sca1, Oct4,
CD133, Hoescht dye efflux, reviewed by Little9). Some of
these cells demonstrated multipotentiality in vitro and the
ability to apparently engraft within tubules after injury.
Observations in lower vertebrates that de novo nephrogenesis
can be induced in adult kidneys by injury or partial resection,
in a process involving condensation of interstitial, mesen-
chymal cells which appears to recapitulate developmental
nephrogenesis, provided further indirect evidence in support
of the persistence of a kidney mesenchymal progenitor.10
To definitively test whether an endogenous interstitial
stem cell population might contribute to the epithelial
lineage during mammalian renal repair, all mesenchyme-
derived renal epithelial cells were genetically labeled using a
Cre/Lox strategy. The Six2 gene is expressed exclusively
in metanephric mesenchyme cells fated to become renal
epithelia,11 and we crossed a transgenic mouse in which the
Six2 promoter drives the expression of a GFP-Cre recombi-
nase fusion protein (the Six2-GC mouse) against two
different reporter mice, the Rosa26-stop-LacZ (R26R)
reporter and the ACTB-Bgeo,-DsRed.MST reporter (Z/Red).
Because the Six2 gene is active very early in nephrogenesis,
recombination efficiency is high and 95% labeling of all
tubular epithelial cells derived from the metanephric
mesenchyme was achieved (collecting duct epithelia are
derived from the ureteric bud, and therefore not labeled in
this model).12 The rationale is outlined in Figure 2a. As
interstitial cells are not labeled in this model, and as the Six2
locus is not active in the disease model, dilution of the fate
marker following a cycle of injury and repair would provide
evidence of contribution to the epithelial lineage by unlabeled
interstitial cells or possibly circulating cells. If all the cells of
repaired tubules continue to express the fate marker, by
contrast, then repairing epithelial cells originate from within
the tubule.
After close inspection of adult kidney sections, we could
find no interstitial cells that expressed either the LacZ or RFP
fate marker. GFPCre fusion protein expression was unde-
tectable after the completion of nephrogenesis (P3–5),
whether assessed by epifluorescence or antibody-based
detection of GFP (the GFPCre fusion protein retains GFP
fluorescence), Six2 transcripts, or Six2 protein using a specific
antiserum (as GFPCre expression is regulated by the Six2
promoter, the GFP expression pattern mirrors the expression
of endogenous Six2 mRNA and protein). Mice were
subjected to renal ischemia–reperfusion injury to trigger the
proliferative response. At 2 days after injury, 47.4% of cells in
the outer medulla expressed the proliferation marker Ki67
and all these cells co-expressed the epithelial fate marker RFP.
Many tubules had flattened epithelial cells characteristic of
the dedifferentiated state, and these cells also expressed either
RFP or LacZ fate markers (Six2-GC; Z/Red or Six2-GC; R26R
mice, respectively). When mice were injured and given an
injection of BrdU once daily for 7 days, 66.9% of outer
medulla epithelial cells had incorporated BrdU, compared
with 3.5% in uninjured, control kidneys. Despite this robust
Table 1 | Recombinases available for fate mapping
Recombinase Advantage Disadvantage
Cre recombinase Many available lines May mark too broad
a range of cells
Flp recombinases Different variants with
high to low activity
Few mouse lines
available
CreER/FlpER
recombinases
Temporal control over
recombination event
Fewer lines available
Table 2 | Selection of reporters available for fate mapping
Reporter Advantage Disadvantage
R26-LacZ Ubiquitous expression,
easy to visualize,
validated in kidney
Immunofluorescence very
difficult in adult kidney, lower
resolution than fluorescent tags
R26-yellow
fluorescent
protein
Immunofluorescent tag
allows high-resolution
imaging
Relatively low intrinsic
expression in adult kidney
Z/Red43 High-resolution
fluorescence imaging
Mice are difficult to breed, will
not go homozygous
R26-mT/mG44 Bright expression in
kidney, membrane
targeting may help
visualize certain cells
Costaining options limited as
red and green fluorescence is
present, membrane staining not
optimal for all tubular epithelial
cells
R26-CAG-
tdTomato45
Robust epifluorescence,
can be maintained as
homozygote
R26-nuclear
LacZ/GFP46
Allows dual Cre and flp
recombination tracing
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proliferation, there was no dilution of the fate marker in
kidneys that had been allowed to repair for 15 days. A total of
94.3±3.7% of outer medullary epithelia were RFPþ before
injury, and 94.4±2.4% expressed RFP after repair, with
similar results calculated for LacZ as the fate marker.12
If the GFPCre fusion protein were reexpressed in epithelial
cells after injury, then a non-labeled interstitial cell that had
migrated into the damaged tubule might also be induced to
express GFPCre, and thus activate the expression of
either RFP or LacZ, compromising our ability to detect a
dilution of the fate marker. However, we did not detect
reexpression of the transgene, as assessed by sensitive GFP
immunofluorescence despite very robust GFP fluorescence in
the cap mesenchyme of P1 kidneys from Six2-GC mice, a
stage where Six2 is still expressed. We were also unable to
detect Cre mRNA after injury by qualitative reverse
transcription-PCR, and we did not detect endogenous Six2
protein in adult kidney after injury using a specific anti-Six2
antibody.
To verify these results, we also performed the converse
experiment by labeling interstitial but not epithelial cells,
using a FoxD1-Cre driver. In this case, the interstitial
compartment, including pericytes, vascular smooth muscle
cells and mesangium, was efficiently labeled. After a cycle of
injury and repair, there was no increase in labeled epithelial
cells in the tubule, providing further strong evidence against
the possibility that an interstitial cell population is capable
of contributing to the epithelial lineage during endogenous
repair.
These results do not rule out a role for cell fusion in
kidney repair, as a cell that did not express the fate marker,
fusing with one that did, would take on expression of the
reporter. However, cell fusion has been found to have a very
small role in endogenous kidney repair from ischemia–
reperfusion injury with o1% of tubular epithelial cells
undergoing fusion with bone marrow-derived cells.13 These
results do not rule out that a unipotent intratubular epithelial
progenitor population might exist, which selectively expands
after ischemic injury, as we genetically labeled all cells within the
tubule. Arguing against this possibility, in mercuric chloride-
induced toxic renal injury, the great majority of epithelial
cells were observed to reenter the cell cycle,14 however, this
remains to be investigated in ischemic injury and repair.
Though unlikely, it is formally possible given the kidney’s
complex anatomy that we failed to detect a rare interstitial
Labeled
tubule
IRI
Repair
1
2
Labeled
tubule
UUO
Fibrosis
1
2
Labeled
interstitium
UUO
Fibrosis
1
2
Figure 2 |Application of genetic fate mapping to kidney injury
and fibrosis. (a) Fate mapping strategy used to distinguish
epithelial repair by surviving epithelial cells or by extratubular
stem cells. In Six2-GC; R26R mice, all renal epithelial cells express
the genetic fate marker, but no non-epithelial, stromal cell is
labeled. After ischemic injury, many labeled cells die by apoptosis
or necrosis. After repair is complete, if tubules remain completely
labeled (1) then surviving epithelial cells were responsible for
repair. Dilution of the fate marker in repaired nephrons (2) would
indicate repair by an extratubular stem cell. (b) To test the
epithelial-to-mesenchymal transition (EMT) hypothesis, mice with
genetically labeled epithelia but not stroma were subject to
fibrotic injury (unilateral ureteral obstriction (UUO)). After fibrosis,
the absence of labeled myofibroblasts (1) would indicate that
epithelia had not migrated across the basement membrane to
become myofibroblasts in a process of EMT. The presence of
myofibroblasts expressing the fate marker in a proportion of
myofibroblasts (2) would indicate that EMT had occurred. (c) To
definitively lineage trace myofibroblast precursors, kidney stroma
was labeled using FoxD1-GC; R26R bigenic mice. Pericytes,
perivascular fibroblasts, mesangium, and vascular smooth muscle
are labeled in this model, but not epithelia. After UUO, the
absence of labeled myofibroblasts in interstitium (1) would
indicate that the myofibroblast precursor does not reside within
descendants of the FoxD1 lineage. Expansion of labeled cells
(2) indicates that FoxD1 descendants contain the myofibroblast
progenitor population. IRI, ischemia–reperfusion injury.
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Figure 3 |Kidney myofibroblasts derived from Pdgfrbþ , CD73þ pericytes and perivascular fibroblasts. (a–c) Descendents of
embryonic cortical interstitial mesenchyme were permanently labeled with LacZ in Foxd1-Cre; Rosa26R mice. These stromal descendants in
adult kidney are vascular smooth muscle, mesangium, pericytes, and perivascular fibroblasts; LacZþ medullary pericytes are shown in (a).
Following unilateral ureteral obstriction (UUO) injury for 14 days, there is marked expansion of the interstitium with LacZþ cells (b) and
498% of the LacZþ cells express a-smooth muscle actin (aSMA) in disease (c). Because Foxd1 is reactivated in disease, a cohort of
pericytes/perivascular fibroblasts was labeled at embryonic day 10.5 during development only in Foxd1-CreERT2; Rosa26R mice by tamoxifen
(tam) injection. Approximately 20% of all pericytes/perivascular fibroblasts were labeled by this method in normal adult kidney (d).
Following UUO kidney injury, the cohort of labeled cells expands 15-fold (e) and all the cells are aSMAþ and comprise 20% of the total
aSMAþ myofibroblast pool (not shown). In identical mice that did not receive tam injection in utero, there were no LacZþ cells indicating
that the LacZ reporter cannot be activated in disease (f). (g) Electron micrographs of glutaraldehyde-fixed normal rat kidneys
immunolabeled with anti-fibronectin antibodies (intense black deposition). Image on left shows a two capillary lumina (A, B), endothelial
cell body (E), and pericyte body (P). Two pericyte processes (Pp) are labeled. Fibronectin is deposited at adhesion sites between endothelial
cells and pericytes (arrows) and direct apposition of Pp and endothelial cell without fibronectin deposition is shown (arrow heads). Pp
adhesion to dense extracellular matrix is shown (double arrows;  14,500). Image on right shows fenestrated endothelium largely covered
by pericyte processes. Fibronectin is discontinuously found at pericyte-endothelial adhesions. No fibronectin is detected in capillary
basement membrane (CBM) proper (arrow heads) or at tubule basement membrane (T) or collagen bundles (CB;  20,000). (h) EM of
glutaraldehyde-fixed normal rat kidney immunolabeled with anti-fibronectin antibodies showing pericyte process (Pp) and endothelial cell
(E). Fibronectin is seen exclusively at adhesion or close apposition sites in the endothelial pericyte interstitial space. Note the discontinuous
CBM between pericyte process and endothelium and note the overlying CBM proper ( 43,000). (i) Conventional EM image showing focal
relationships between the endothelium (E) and the pericyte (P). Numerous microfilaments originate or insert in the dense plaque (long
arrows) associated with the fusion of the pericyte’s basement membrane (arrow heads) with that of the nearby tubule (T). These filaments
parallel the capillary endothelium and run through three densities (1, 2, and 3). Plaques 1 and 3 are associated with sparse extracellular
material and plaque 2 with a close apposition of the endothelial cell. A second close apposition is not associated with any density or
filaments (short arrows). Finally, interposition of a well-organized basement membrane (BM) is visible at the lower left ( 38,400).
(g–i reproduced from Courtoy and Boyles36.)
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cell population that could have contributed to endogenous
epithelial repair.
It is worth noting that recent genetic fate mapping studies
in other organs has led to a reappraisal of previously accepted
regeneration models. In pancreas, where self-duplication of
differentiated b-cells had been the accepted model in
homeostasis and in repair from injury,15 an unexpected
plasticity of non-b cells has recently been observed using
more severe injury models than previously employed.
Neurogenin-3þ pancreatic ductal cells can be selectively
recruited to differentiate into all islet cell types after severe
injury.16 More surprisingly, after extreme b-cell loss (495%),
a-cells spontaneously convert to b-cells, revealing a pre-
viously undiscovered inherent plasticity of the differentiated
state.17 Whether such unexpected mechanisms of regenera-
tion might exist in kidney is unknown. In skin, separate stem
cell populations had been believed to maintain interfollicular
epidermis, sebaceous glands, and hair follicles.18 Recently,
however, Lgr6 has been identified as a marker of multipotent
skin stem cells, able to contribute to all three skin lineages.
Snippert et al.19 utilized lineage tracing to show that Lgr6þ
cells contribute to all three lineages during development, and
in adult homeostasis these cells contributed mainly to
interfollicular epidermis and sebaceous glands, but could be
recruited to contribute to hair follicle lineage after injury.
These surprising results establish Lgr6þ cells as the most
primitive epidermal stem cell thus far characterized, and
demonstrate the power of genetic fate mapping to establish
cell hierarchies during homeostasis and repair.
These recent findings in pancreas and skin illustrate the
varied strategies for regeneration that may exist within a
single organ. An emerging theme is that there may be
different mechanisms of cell replenishment during homeo-
stasis, mild injury, and severe injury. Clearly, it will be
important to continue to use lineage-tracing techniques in a
variety of kidney injury models of differing severity to fully
elucidate the full spectrum of mechanisms of kidney repair
from acute injury.
FATE MAPPING TO DEFINE MYOFIBROBLAST PROGENITORS
IN FIBROTIC KIDNEY DISEASE
The cellular origin of matrix-forming myofibroblasts in
organ injury has been a subject of intense investigation for
decades. Understanding from which cell-type the activated
myofibroblasts derive is a prerequisite for the design of
targeted therapies to slow or reverse progressive fibrotic
diseases. Resident fibroblasts, perivascular adventitial cells,
and circulating fibroblast precursors have all been implicated
as sources for the interstitial myofibroblast population. In
addition, for the last decade, a central tenet of the kidney
fibrosis field has been that a large proportion of interstitial
myofibroblasts originate from tubular epithelial cells that
have undergone the process of epithelial-to-mesenchymal
transition (EMT).20–22 The model holds that terminally
differentiated epithelial cells, under conditions of chronic
injury that alter the balance of local cytokines, dedifferentiate
and express mesenchymal proteins, traverse the basement
membrane into the interstitium where they ‘transdifferen-
tiate’ into a myofibroblast phenotype capable of laying down
pathological matrix.
The experimental data supporting this conclusion rest on
several lines of inquiry. First, histological analysis of injured
kidney sections has shown colocalization of epithelial cell
markers such as Naþ , Kþ -ATPase and myofibroblast
markers such as smooth muscle actin (SMA) or fibroblast-
specific protein-1, suggesting an intermediate cell type caught
in transition from epithelial to fibroblast. Second, primary
epithelial cells when cultured in vitro with tumor growth
factor-b can be activated to express mesenchymal and
myofibroblast markers and adopt a spindle morphology.23
This in vitro demonstration of EMT provides supportive
evidence that the same process might occur in vivo. Finally,
there has been one study utilizing cell lineage analysis and
Cre/Lox techniques to track the cell fate of renal epithelia
during fibrotic disease. In this study, the transgenic renal
proximal tubule promoter g-glutamyl transferase drove the
expression of Cre recombinase, in R26R reporter mice.24
Using the unilateral ureteral obstriction model of interstitial
fibrosis, LacZþ cells could be detected in the interstitium by
immunofluorescent detection of LacZ using antibodies
against b-galactosidase. No confirmatory study using lineage
analysis has been published.
Despite the widespread acceptance of the relevance of
EMT to progressive fibrotic disease,25 most in vivo evidence
supporting the theory has relied on histological snap shots
rather than genetic lineage analysis. To test the EMT
hypothesis in fibrotic kidney disease using a fate mapping
approach, we genetically labeled all renal epithelial cells in
kidney using the Six2-cre driver, which labels metanephric
mesenchyme-derived epithelia, and the HoxB7-cre driver,
which labels ureteric bud-derived collecting duct epithelia
(Figure 2b and c). We incorporated the Cre drivers in both
the R26R and Z/Red reporter mice. Using two models of
fibrotic disease, unilateral ureteral obstruction unilateral
ureteral obstriction and unilateral ischemia–reperfusion
injury, we were unable to detect any genetically labeled cells
in the interstitium, despite abundant appearances of aSMAþ
myofibroblasts.26 By contrast, when we cultured primary
renal epithelial cells in vitro from these mice and incubated
with tumor growth factor-b, the DsRedþ epithelial cells
readily expressed aSMA and lost E-cadherin expression, a
reported characteristic of EMT.
These findings indicate that although phenotypic changes
reported to represent EMT can occur in vitro, an EMT
process does not directly contribute to the interstitial
myofibroblast pool in vivo. To determine which cells are the
myofibroblast progenitor pool in vivo, we genetically labeled
kidney stromal cells using the FoxD1-Cre driver. FoxD1 is a
transcription factor expressed during nephrogenesis in cells
surrounding the cap condensate and they are fated to become
pericytes, perivascular fibroblasts, vascular smooth muscle,
and mesangium.27,28 FoxD1-Cre; R26R bigenic healthy kidneys
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showed strong b-galactosidase (LacZ product) expression in
interstitial cells in both cortex and medulla that were CD31,
F4/80, aSMA but CD73þ and PDGFRbþ . After unilateral
ureteral obstriction, this population expanded markedly and
gained expression of aSMA, indicating that the FoxD1-labeled
progenitors became myofibroblasts (Figure 3a–c).
While this experiment provided support for a model in
which a FoxD1-labeled cell population, most likely interstitial
pericytes,29 selectively expands in fibrotic disease and become
myofibroblasts, we could detect reactivation of the FoxD1 gene in
injury of adult kidney, compromising our ability to distinguish
proliferation and differentiation of previously labeled cells from
activation of Cre in an unlabeled cell type (such as epithelium)
with new expression of the reporter. Although this is highly
unlikely as FoxD1 expression does not occur in injured
epithelium but appears restricted to myofibroblasts, vascular
smooth muscle cells, and mesangium, we nevertheless
utilized an inducible CreERt2 driven at the FoxD1 locus
in R26R mice. Mouse embryos were exposed in utero to
tamoxifen, which triggers the translocation of the CreER
protein to the nucleus making a FoxD1þ cell transiently
permissive to recombination at the R26R locus. Because
tamoxifen is toxic at high doses, we were able to label with a
single dose, a cohort of 20% of all the interstitial pericytes/
perivascular fibroblasts. After unilateral ureteral obstriction
in adult kidney, this cohort of pulse-genetically-labeled pericytes
expanded 15-fold, all acquired aSMA expression, and repre-
sented 20% of the total myofibroblast pool (Figure 3d–f).
These provided unequivocal results implicating the interstitial
pericyte/perivascular fibroblast as the myofibroblast progeni-
tor. Moreover, these studies did not support a model where
significant additional myofibroblast progenitors play a role.
It should be noted that recent fate mapping results in
liver have prompted a reanalysis of the existence of EMT
in liver fibrosis, with recent evidence suggesting that it does
not have a direct role,30,31 consistent with our findings in
kidney. Moreover, since our initial publication, two other
reports using genetic fate mapping approaches and a third
fibrotic model have also failed to observe evidence for any
contribution of epithelial cells to the interstitial myofibroblast
pool, bringing the number of independent groups failing to
detect EMT to three.32,33 Finally, these findings are consistent
with recent morphological observations that also implicate
peritubular fibroblasts as the myofibroblast progenitor.34
Although these studies place renewed emphasis on kidney
pericytes/perivascular fibroblasts, these cells are quite numer-
ous. One pericyte is present for every four endothelial cells
and they are an integral part of the peritubular capillaries and
post capillary venules. Surrounding arterioles, they are called
perivascular fibroblasts and lie adherent to the vessel wall but
not in direct communication with endothelial cells.29,35
Kidney pericytes were first reported unequivocally in rat by
electron micrographic studies in 198336 (Figure 3g–h), and
were initially described in other tissue beds by Rouget37 and
Zimmerman.38 They are extensively branched cells that
partially surround the endothelium of capillaries. Kidney
pericytes, as described by Courtoy and Boyles,36 fulfill the
criteria for pericytes because they are sheathed with basement
membrane which is believed to be a duplication of capillary
basement membrane; the capillary basement membrane is
frequently incomplete between pericyte and endothelial cell
allowing close apposition or interdigitation to occur; at these
sites are adhesion plaques, peg and socket projections, and
other sites of cell–cell signaling. Whereas pericyte processes
are always covered by capillary basement membrane, this
coverage may be incomplete or partial over the cell bodies.39
In the kidney, however, some of these pericytes also have
projections that abut the tubular basement membrane and
may be able to signal bilaterally with epithelium as well as
endothelium, and in this context several groups have called
these cells resident fibroblasts.40,41
Together, these results raise many questions:
1. What is the relationship to fibrosis of the mesenchymal
transformation that epithelial cells undergo in conditions
of chronic injury in the absence of transition to
myofibroblasts? There is a rich literature linking elabora-
tion of pro-fibrogenic cytokines by epithelial cells to
fibrogenesis and it is likely that paracrine signaling from
the epithelium to the pericyte is part of the answer;
2. What signaling pathways and transcriptional circuitry
regulate the epithelial dedifferentiation, and can these
pathways be regulated for therapeutic purposes?
3. What is the consequence of pericyte/perivascular fibroblast
migration from capillaries on the renal microvasculature?
4. Are there differences among the FoxD1-labeled interstitial
cells, pericytes and perivascular fibroblasts in particular, in
their ability to be recruited into the myofibroblast pool? It
is very likely that, in fact, this is a heterogeneous group of
cells, and understanding these differences, for example,
between cortical pericytes and medullary pericytes,
requires investigation;
5. As pericytes have been proposed to be tissue-specific
mesenchymal stem cells,42 it will be important to purify
these cells, devise conditions for their culture, and assess
their multipotentiality.
CONCLUSIONS
Lineage analysis has proved to be an invaluable tool for the
study of cell lineage in kidney homeostasis and repair. There
is no doubt that this powerful technique will continue to
have an important role in defining cellular hierarchies in
kidney diseases. This knowledge is important, as it clarifies
the appropriate cell types to the target, in order to develop
new therapies for the treatment of acute and chronic kidney
disease in humans.
DISCLOSURE
All the authors declared no competing interests.
REFERENCES
1. Conklin EG. The organization and cell lineage of the ascidian egg.
J Acad Nat Sci Phil 1905; 12: 1–119.
500 Kidney International (2011) 79, 494–501
min i rev iew JS Duffield and BD Humphreys: Origin of new cells in the adult kidney
2. Vogt W. Gestaltungsanalyse am Amphibienkeim mit ortlicher
Vitalfarbung. II. Teil Gastrulation und Mesodermbildung bie Urodelen und
Anuren. Wilhelm Roux Arch Entwicklungsmech Org 1929; 120: 384–706.
3. Le Douarin NM. The Neural Crest. Cambridge University Press: Cambridge,
1982.
4. Clarke JD, Tickle C. Fate maps old and new. Nat Cell Biol 1999; 1:
E103–E109.
5. Joyner AL, Zervas M. Genetic inducible fate mapping in mouse:
establishing genetic lineages and defining genetic neuroanatomy in the
nervous system. Dev Dyn 2006; 235: 2376–2385.
6. Hayashi S, McMahon AP. Efficient recombination in diverse tissues by a
tamoxifen-inducible form of Cre: a tool for temporally regulated gene
activation/inactivation in the mouse. Dev Biol 2002; 244: 305–318.
7. Messier B, Leblond CP. Cell proliferation and migration as revealed by
radioautography after injection of thymidine-H3 into male rats and mice.
Am J Anat 1960; 106: 247–285.
8. Witzgall R, Brown D, Schwarz C et al. Localization of proliferating cell
nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney.
Evidence for a heterogenous genetic response among nephron
segments, and a large pool of mitotically active and dedifferentiated cells.
J Clin Invest 1994; 93: 2175–2188.
9. Little MH. Regrow or repair: potential regenerative therapies for the
kidney. J Am Soc Nephrol 2006; 17: 2390–2401.
10. Elger M, Hentschel H, Litteral J et al. Nephrogenesis is induced by partial
nephrectomy in the elasmobranch Leucoraja erinacea. J Am Soc Nephrol
2003; 14: 1506–1518.
11. Kobayashi A, Valerius MT, Mugford JW et al. Six2 defines and regulates a
multipotent self-renewing nephron progenitor population throughout
mammalian kidney development. Cell Stem Cell 2008; 3: 169–181.
12. Humphreys BD, Valerius MT, Kobayashi A et al. Intrinsic epithelial cells
repair the kidney after injury. Cell Stem Cell 2008; 2: 284–291.
13. Li L, Truong P, Igarashi P et al. Renal and bone marrow cells fuse after
renal ischemic injury. J Am Soc Nephrol 2007; 18: 3067–3077.
14. Vogetseder A, Picard N, Gaspert A et al. Proliferation capacity of the
renal proximal tubule involves the bulk of differentiated epithelial cells.
Am J Physiol Cell Physiol 2008; 294: C22–C28.
15. Dor Y, Brown J, Martinez OI et al. Adult pancreatic beta-cells are formed
by self-duplication rather than stem-cell differentiation. Nature 2004; 429:
41–46.
16. Xu X, D’Hoker J, Stange G et al. Beta cells can be generated from
endogenous progenitors in injured adult mouse pancreas. Cell 2008; 132:
197–207.
17. Thorel F, Nepote V, Avril I et al. Conversion of adult pancreatic alpha-cells
to beta-cells after extreme beta-cell loss. Nature 2010; 464: 1149–1154.
18. Fuchs E, Horsley V. More than one way to skin. Genes Dev 2008; 22:
976–985.
19. Snippert HJ, Haegebarth A, Kasper M et al. Lgr6 marks stem cells in the
hair follicle that generate all cell lineages of the skin. Science 2010; 327:
1385–1389.
20. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis:
pathologic significance, molecular mechanism, and therapeutic
intervention. J Am Soc Nephrol 2004; 15: 1–12.
21. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its
implications for fibrosis. J Clin Invest 2003; 112: 1776–1784.
22. Iwano M, Neilson EG. Mechanisms of tubulointerstitial fibrosis.
Curr Opin Nephrol Hypertens 2004; 13: 279–284.
23. Li Y, Yang J, Dai C et al. Role for integrin-linked kinase in mediating
tubular epithelial to mesenchymal transition and renal interstitial
fibrogenesis. J Clin Invest 2003; 112: 503–516.
24. Iwano M, Plieth D, Danoff TM et al. Evidence that fibroblasts derive
from epithelium during tissue fibrosis. J Clin Invest 2002; 110: 341–350.
25. Thiery JP, Acloque H, Huang RY et al. Epithelial-mesenchymal transitions
in development and disease. Cell 2009; 139: 871–890.
26. Humphreys BD, Lin SL, Kobayashi A et al. Fate tracing reveals the pericyte
and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol
2010; 176: 85–97.
27. Hatini V, Huh SO, Herzlinger D et al. Essential role of stromal mesenchyme
in kidney morphogenesis revealed by targeted disruption of winged helix
transcription factor BF-2. Genes Dev 1996; 10: 1467–1478.
28. Levinson RS, Batourina E, Choi C et al. Foxd1-dependent signals control
cellularity in the renal capsule, a structure required for normal renal
development. Development 2005; 132: 529–539.
29. Lin SL, Kisseleva T, Brenner DA et al. Pericytes and perivascular fibroblasts
are the primary source of collagen-producing cells in obstructive fibrosis
of the kidney. Am J Pathol 2008; 173: 1617–1627.
30. Wells RG. The epithelial-to-mesenchymal transition in liver fibrosis:
here today, gone tomorrow? Hepatology 2010; 51: 737–740.
31. Taura K, Miura K, Iwaisako K et al. Hepatocytes do not undergo
epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology
2010; 51: 1027–1036.
32. Li L, Zepeda-Orozco D, Black R et al. Autophagy is a component of
epithelial cell fate in obstructive uropathy. Am J Pathol 2010; 176:
1767–1778.
33. Koesters R, Kaissling B, Lehir M et al. Tubular overexpression of
transforming growth factor-beta1 induces autophagy and fibrosis
but not mesenchymal transition of renal epithelial cells. Am J Pathol
2010; 177: 632–643.
34. Picard N, Baum O, Vogetseder A et al. Origin of renal myofibroblasts
in the model of unilateral ureter obstruction in the rat. Histochem Cell
Biol 2008; 130: 141–155.
35. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions.
Circ Res 2005; 97: 512–523.
36. Courtoy P, Boyles J. Fibronectin in the microvasculature: localization in
the pericyte-endothelial interstitium. J Ultrastruct Res 1983; 83: 258–273.
37. Rouget C. Memoire sur le developpement, la structure et les proprietes
physiologiques des capillaries sanguins et lymphatiques. Arch Physiol
Norm Pathol 1873; 5: 603–663.
38. Zimmerman K. Der feinere bau der blutcapillaren. Z Anat
Entwicklungsgeschichte 1923; 68: 29–36.
39. Rhodin JA. Ultrastructure of mammalian venous capillaries, venules, and
small collecting veins. J Ultrastruct Res 1968; 25: 452–500.
40. Kaissling B, Hegyi I, Loffing J et al. Morphology of interstitial cells in the
healthy kidney. Anat Embryol (Berl) 1996; 193: 303–318.
41. Lemley KV, Kriz W. Anatomy of the renal interstitium. Kidney Int 1991; 39:
370–381.
42. Crisan M, Yap S, Casteilla L et al. A perivascular origin for mesenchymal
stem cells in multiple human organs. Cell Stem Cell 2008; 3: 301–313.
43. Vintersten K, Monetti C, Gertsenstein M et al. Mouse in red: red
fluorescent protein expression in mouse ES cells, embryos, and adult
animals. Genesis 2004; 40: 241–246.
44. Muzumdar MD, Tasic B, Miyamichi K et al. A global double-fluorescent Cre
reporter mouse. Genesis 2007; 45: 593–605.
45. Madisen L, Zwingman TA, Sunkin SM et al. A robust and high-throughput
Cre reporting and characterization system for the whole mouse brain. Nat
Neurosci 2010; 13: 133–140.
46. Yamamoto M, Shook NA, Kanisicak O et al. A multifunctional reporter
mouse line for Cre- and FLP-dependent lineage analysis. Genesis 2009; 47:
107–114.
Kidney International (2011) 79, 494–501 501
JS Duffield and BD Humphreys: Origin of new cells in the adult kidney m in i rev iew
